Recent advances in lipid nanovesicles for targeted treatment of spinal cord injury

Frontiers in Bioengineering and Biotechnology

Bioengineering and Biotechnology

Chen Wang¹  Yan-Lian Yang²  Hua-Yi Wang²  Ling Zhu²  Jiu-Ping Wu³  Xin-Zhi Sun³  Gang-Gang Zhang³  Jun-Jie Yang³  Qi-Wei Yang⁴  Di Lu⁴ 

[1] CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nano-science and Technology, Beijing, China;CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, China;CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nano-science and Technology, Beijing, China;University of Chinese Academy of Sciences, Beijing, China;Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nano-science and Technology, Beijing, China;

关键词: spinal cord injury;    lipid nanovesicles;    liposomes;    extracellular vesicles;    targeting;    drug delivery;   

DOI  :  10.3389/fbioe.2023.1261288

 received in 2023-07-19, accepted in 2023-08-07,  发布年份 2023

来源: Frontiers

【 摘 要 】

The effective regeneration and functional restoration of damaged spinal cord tissue have been a long-standing concern in regenerative medicine. Treatment of spinal cord injury (SCI) is challenging due to the obstruction of the blood-spinal cord barrier (BSCB), the lack of targeting of drugs, and the complex pathophysiology of injury sites. Lipid nanovesicles, including cell-derived nanovesicles and synthetic lipid nanovesicles, are highly biocompatible and can penetrate BSCB, and are therefore effective delivery systems for targeted treatment of SCI. We summarize the progress of lipid nanovesicles for the targeted treatment of SCI, discuss their advantages and challenges, and provide a perspective on the application of lipid nanovesicles for SCI treatment. Although most of the lipid nanovesicle-based therapy of SCI is still in preclinical studies, this low immunogenicity, low toxicity, and highly engineerable nanovesicles will hold great promise for future spinal cord injury treatments.

【 授权许可】

Unknown   
Copyright © 2023 Lu, Wu, Yang, Wang, Yang, Zhang, Wang, Yang, Zhu and Sun.